Gebruers Nick, Verbelen Hanne, De Vrieze Tessa, Coeck Dorith, Tjalma Wiebren
Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Department of Rehabilitation Sciences and Physiotherapy, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Arch Phys Med Rehabil. 2015 Jun;96(6):1131-9. doi: 10.1016/j.apmr.2015.01.014. Epub 2015 Jan 28.
To systematically assess the incidence/prevalence and time path of lymphedema in patients with sentinel node-negative breast cancer.
A systematic literature search up to November 2013 was performed using 4 different electronic databases: PubMed, Embase, Cochrane Clinical Trials, and Web of Science.
Inclusion criteria were as follows: (1) research studies that included breast cancer patients who were surgically treated using the sentinel lymph node biopsy (SLNB) technique; (2) sentinel node-negative patients; (3) studies that investigated lymphedema as a primary or secondary outcome; (4) data extraction for the incidence or time path of lymphedema was possible; and (5) publication date starting from January 1, 2001. Exclusion criteria were as follows: (1) reviews or case studies; (2) patients who had an SLNB followed by an axillary lymph node dissection (ALND); (3) results of ALND patients and SLNB patients not described separately; and (4) studies not written in English.
After scoring the methodological quality of the selected studies, the crude data concerning the incidence of lymphedema were extracted. Data concerning the time points and the incidence of lymphedema were also extracted.
Twenty-eight articles were included, representing 9588 SLNB-negative patients. The overall incidence of lymphedema in patients with sentinel node-negative breast cancer ranged from 0% to 63.4%. The studies that have assessed lymphedema at predefined time points, instead of a mean follow-up time, demonstrated an incidence range at ≤3, 6, 12, 18, or >18 months postsurgery of 3.2% to 5%, 2% to 10%, 3% to 63.4%, 6.6% to 7%, and 6.9% to 8.2%, respectively.
In SLNB patients, lymphedema is still a problem, mostly occurring 6 to 12 months after surgery. Because of different assessments and criteria, there is a wide range in incidence. Clear definitions of lymphedema are absolutely necessary to tailor therapy.
系统评估前哨淋巴结阴性乳腺癌患者淋巴水肿的发病率/患病率及时间变化轨迹。
截至2013年11月,使用4个不同的电子数据库进行了系统文献检索:PubMed、Embase、Cochrane临床试验库和科学网。
纳入标准如下:(1)纳入采用前哨淋巴结活检(SLNB)技术进行手术治疗的乳腺癌患者的研究;(2)前哨淋巴结阴性患者;(3)将淋巴水肿作为主要或次要结局进行研究的研究;(4)能够提取淋巴水肿发病率或时间变化轨迹的数据;(5)出版日期从2001年1月1日开始。排除标准如下:(1)综述或病例研究;(2)接受SLNB后又进行腋窝淋巴结清扫(ALND)的患者;(3)未分别描述ALND患者和SLNB患者结果的研究;(4)非英文撰写的研究。
在对所选研究的方法学质量进行评分后,提取有关淋巴水肿发病率的原始数据。还提取了有关时间点和淋巴水肿发病率的数据。
纳入了28篇文章,代表9588例SLNB阴性患者。前哨淋巴结阴性乳腺癌患者淋巴水肿的总体发病率为0%至63.4%。在预定时间点而非平均随访时间评估淋巴水肿的研究显示,术后≤3、6、12、18或>18个月时的发病率范围分别为3.2%至5%、2%至10%、3%至63.4%、6.6%至7%和6.9%至8.2%。
在SLNB患者中,淋巴水肿仍是一个问题,主要发生在术后6至12个月。由于评估和标准不同,发病率范围较广。明确淋巴水肿的定义对于制定治疗方案绝对必要。